Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 95

Similar articles for PubMed (Select 23966247)

1.

HTRF analysis of soluble huntingtin in PHAROS PBMCs.

Moscovitch-Lopatin M, Goodman RE, Eberly S, Ritch JJ, Rosas HD, Matson S, Matson W, Oakes D, Young AB, Shoulson I, Hersch SM; Huntington Study Group PHAROS Investigators.

Neurology. 2013 Sep 24;81(13):1134-40. doi: 10.1212/WNL.0b013e3182a55ede. Epub 2013 Aug 21.

2.

Optimization of an HTRF Assay for the Detection of Soluble Mutant Huntingtin in Human Buffy Coats: A Potential Biomarker in Blood for Huntington Disease.

Moscovitch-Lopatin M, Weiss A, Rosas HD, Ritch J, Doros G, Kegel KB, Difiglia M, Kuhn R, Bilbe G, Paganetti P, Hersch S.

PLoS Curr. 2010 Dec 29;2:RRN1205. doi: 10.1371/currents.RRN1205.

3.

Characterization of the Huntington intermediate CAG repeat expansion phenotype in PHAROS.

Killoran A, Biglan KM, Jankovic J, Eberly S, Kayson E, Oakes D, Young AB, Shoulson I.

Neurology. 2013 May 28;80(22):2022-7. doi: 10.1212/WNL.0b013e318294b304. Epub 2013 Apr 26.

4.

Relationship of Mediterranean diet and caloric intake to phenoconversion in Huntington disease.

Marder K, Gu Y, Eberly S, Tanner CM, Scarmeas N, Oakes D, Shoulson I; Huntington Study Group PHAROS Investigators.

JAMA Neurol. 2013 Nov;70(11):1382-8. doi: 10.1001/jamaneurol.2013.3487.

5.

Polyglutamine domain flexibility mediates the proximity between flanking sequences in huntingtin.

Caron NS, Desmond CR, Xia J, Truant R.

Proc Natl Acad Sci U S A. 2013 Sep 3;110(36):14610-5. doi: 10.1073/pnas.1301342110. Epub 2013 Jul 29.

6.

Wild type Huntingtin reduces the cellular toxicity of mutant Huntingtin in mammalian cell models of Huntington's disease.

Ho LW, Brown R, Maxwell M, Wyttenbach A, Rubinsztein DC.

J Med Genet. 2001 Jul;38(7):450-2.

7.

A critical window of CAG repeat-length correlates with phenotype severity in the R6/2 mouse model of Huntington's disease.

Cummings DM, Alaghband Y, Hickey MA, Joshi PR, Hong SC, Zhu C, Ando TK, André VM, Cepeda C, Watson JB, Levine MS.

J Neurophysiol. 2012 Jan;107(2):677-91. doi: 10.1152/jn.00762.2011. Epub 2011 Nov 9.

8.

Single-step detection of mutant huntingtin in animal and human tissues: a bioassay for Huntington's disease.

Weiss A, Abramowski D, Bibel M, Bodner R, Chopra V, DiFiglia M, Fox J, Kegel K, Klein C, Grueninger S, Hersch S, Housman D, Régulier E, Rosas HD, Stefani M, Zeitlin S, Bilbe G, Paganetti P.

Anal Biochem. 2009 Dec 1;395(1):8-15. doi: 10.1016/j.ab.2009.08.001. Epub 2009 Aug 6.

PMID:
19664996
9.

Development of an ELISA assay for the quantification of soluble huntingtin in human blood cells.

Massai L, Petricca L, Magnoni L, Rovetini L, Haider S, Andre R, Tabrizi SJ, Süssmuth SD, Landwehrmeyer BG, Caricasole A, Pollio G, Bernocco S.

BMC Biochem. 2013 Nov 25;14:34. doi: 10.1186/1471-2091-14-34.

10.

Autopsy-proven Huntington's disease with 29 trinucleotide repeats.

Kenney C, Powell S, Jankovic J.

Mov Disord. 2007 Jan;22(1):127-30.

PMID:
17115386
11.

Dietary intake in adults at risk for Huntington disease: analysis of PHAROS research participants.

Marder K, Zhao H, Eberly S, Tanner CM, Oakes D, Shoulson I; Huntington Study Group.

Neurology. 2009 Aug 4;73(5):385-92. doi: 10.1212/WNL.0b013e3181b04aa2.

12.

Genetic background modifies nuclear mutant huntingtin accumulation and HD CAG repeat instability in Huntington's disease knock-in mice.

Lloret A, Dragileva E, Teed A, Espinola J, Fossale E, Gillis T, Lopez E, Myers RH, MacDonald ME, Wheeler VC.

Hum Mol Genet. 2006 Jun 15;15(12):2015-24. Epub 2006 May 10.

13.

Neuronal aggregates are associated with phenotypic onset in the R6/2 Huntington's disease transgenic mouse.

Cowin RM, Roscic A, Bui N, Graham D, Paganetti P, Jankowsky JL, Weiss A, Paylor R.

Behav Brain Res. 2012 Apr 15;229(2):308-19. doi: 10.1016/j.bbr.2011.12.045. Epub 2012 Jan 28.

PMID:
22306231
14.

IRE1 plays an essential role in ER stress-mediated aggregation of mutant huntingtin via the inhibition of autophagy flux.

Lee H, Noh JY, Oh Y, Kim Y, Chang JW, Chung CW, Lee ST, Kim M, Ryu H, Jung YK.

Hum Mol Genet. 2012 Jan 1;21(1):101-14. doi: 10.1093/hmg/ddr445. Epub 2011 Sep 27.

15.

Msh2 acts in medium-spiny striatal neurons as an enhancer of CAG instability and mutant huntingtin phenotypes in Huntington's disease knock-in mice.

Kovalenko M, Dragileva E, St Claire J, Gillis T, Guide JR, New J, Dong H, Kucherlapati R, Kucherlapati MH, Ehrlich ME, Lee JM, Wheeler VC.

PLoS One. 2012;7(9):e44273. doi: 10.1371/journal.pone.0044273. Epub 2012 Sep 7.

16.

Dramatic tissue-specific mutation length increases are an early molecular event in Huntington disease pathogenesis.

Kennedy L, Evans E, Chen CM, Craven L, Detloff PJ, Ennis M, Shelbourne PF.

Hum Mol Genet. 2003 Dec 15;12(24):3359-67. Epub 2003 Oct 21.

17.

Regulator of calcineurin (RCAN1-1L) is deficient in Huntington disease and protective against mutant huntingtin toxicity in vitro.

Ermak G, Hench KJ, Chang KT, Sachdev S, Davies KJ.

J Biol Chem. 2009 May 1;284(18):11845-53. doi: 10.1074/jbc.M900639200. Epub 2009 Mar 6.

18.

Juvenile Huntington's disease: does a dosage-effect pathogenic mechanism differ from the classical adult disease?

Squitieri F, Frati L, Ciarmiello A, Lastoria S, Quarrell O.

Mech Ageing Dev. 2006 Feb;127(2):208-12. Epub 2005 Nov 7. Review.

PMID:
16274727
19.

Sensitive biochemical aggregate detection reveals aggregation onset before symptom development in cellular and murine models of Huntington's disease.

Weiss A, Klein C, Woodman B, Sathasivam K, Bibel M, Régulier E, Bates GP, Paganetti P.

J Neurochem. 2008 Feb;104(3):846-58. Epub 2007 Nov 6.

PMID:
17986219
20.

Analysis of CAG and CCG repeats in Huntingtin gene among HD patients and normal populations of India.

Pramanik S, Basu P, Gangopadhaya PK, Sinha KK, Jha DK, Sinha S, Das SK, Maity BK, Mukherjee SC, Roychoudhuri S, Majumder PP, Bhattacharyya NP.

Eur J Hum Genet. 2000 Sep;8(9):678-82.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk